Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • 5-HT Receptor
    (5)
  • Cholinesterase (ChE)
    (3)
  • AChR
    (2)
  • Dopamine Receptor
    (2)
  • GABA Receptor
    (2)
  • Histamine Receptor
    (2)
  • Serotonin Transporter
    (2)
  • Adrenergic Receptor
    (1)
  • Apoptosis
    (1)
  • Others
    (18)
Filter
Search Result
Results for "

impairments

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    41
    TargetMol | Inhibitors_Agonists
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Natural Products
    1
    TargetMol | Natural_Products
  • Recombinant Protein
    1
    TargetMol | Recombinant_Protein
Escitalopram
Seroplex, S-(+)-Citalopram, (S)-Citalopram
T0185128196-01-0
Escitalopram (Seroplex) is a furancarbonitrile that is one of the SEROTONIN UPTAKE INHIBITORS used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from tardive dyskinesia in preference to tricyclic antidepressants, which aggravate this condition.
  • Inquiry Price
1-2 weeks
Size
QTY
Escitalopram Oxalate
Cipralex, (S)-(+)Citalopram oxalate
T6493219861-08-2
Escitalopram Oxalate ((S)-(+)Citalopram oxalate) is a selective serotonin (5-HT) reuptake inhibitor (SSRI) with Ki of 0.89 nM.
  • Inquiry Price
Size
QTY
AQW051
AQ W051, VQW-765, AQW-051
T26646669770-29-0
AQW051 (VQW-765) is an orally active alpha-7 nicotinic acetylcholine receptor (α7-nAChR) specific activator that interacts with recombinant human α7-nAChR expression (pKD value 7.56). Alpha7-nachr is considered an attractive target for the treatment of cognitive impairments associated with neurological disorders, so VQW-051 is often used in studies of anxiety disorders and acute anxiety.
  • Inquiry Price
6-8 weeks
Size
QTY
TargetMol | Inhibitor Sale
Oxiracetam
ISF2522
T112862613-82-5
Oxiracetam (ISF2522), a cyclic derivative of gamma-aminobutyric acid (GABA), is utilized for the treatment of cognitive impairments.
  • Inquiry Price
Size
QTY
Bay 60-7550
BAY 607550
T14507439083-90-6
Bay 60-7550 is a selective and potent PDE2 inhibitor (Ki: 3.8 nM) that exerts positive inotropic effects on rat heart by increasing PKA-mediated phosphorylation and can be used to ameliorate cognitive impairments and memory disorders.
  • Inquiry Price
7-10 days
Size
QTY
Brilaroxazine
RP5063
T147821239729-06-6
Brilaroxazine (RP5063) is a potent multimodal dopamine 5-HT modulator. Brilaroxazine is a partial agonist of dopamine D2, D3, and D4 receptors, 5-HT1A (Ki =1.5 nM) and 5-HT2A (Ki = 2.5 nM), and has antagonist activity 5-HT2B, and 5-HT7 receptors with Kis of 0.19 nM and 2.7 nM, respectively. Brilaroxazine can be used for research about cognitive impairments in neuropsychiatric and neurological diseases.
  • Inquiry Price
6-8 weeks
Size
QTY
PH-002
T165181311174-68-1
PH-002, an inhibitor targeting the intramolecular domain interaction of apolipoprotein (apo) E4 in neuronal cells, additionally enhances mitochondrial motility and promotes neurite outgrowth, thereby countering related impairments.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
H3R antagonist 4
T200389
H3R antagonist 4 (compound 11l) serves as a dual inhibitor of cholinesterases and histamine H3 receptors (H3R), demonstrating IC50 values of 7.04 μM (eeAChE), 9.73 μM (hAChE)(reversible), and 1.09 nM (H3R). It effectively inhibits both self and Cu2+-induced Aβ1-42 aggregation at 95.48% and 88.63%, respectively, and degrades Aβ1-42 protofibrils with 80.16% and 89.30% efficiency under similar conditions. Additionally, H3R antagonist 4 possesses the chelating capability for biometals Cu2+, Zn2+, Al3+, and Fe2+. It significantly reduces tau protein hyperphosphorylation induced by Aβ1-42, inhibits RSL-3 induced apoptosis and ferroptosis in PC12 cells, and shows optimal blood-brain barrier permeability and intestinal absorption characteristics in hCMEC D3 and hPepT1-MDCK cells, respectively. Moreover, the compound improves learning and memory impairments in an Alzheimer's mouse model induced with scopolamine.
  • Inquiry Price
Size
QTY
CL-13
T201512
CL-13 is an inhibitor of butyrylcholinesterase (BChE), exhibiting an IC50 of 1.15 μM and a selectivity index (SI) of 9.2 for acetylcholinesterase. It demonstrates antioxidative activity in SH-SY5Y cells with a DPPHEC50 of 47.01 μM and has the capacity to chelate metals involved in Aβ aggregation and or oxidative stress, showing no neurotoxicity at concentrations up to 50 μM. CL-13 can also reverse scopolamine-induced cognitive impairments without affecting motor abilities in mice.
  • Inquiry Price
10-14 weeks
Size
QTY
Cinoxopazide
T20194588053-05-8
Cinoxopazide is recognized for its potential to enhance cognitive efficiency in healthy individuals, support brain function in the elderly, and address issues arising from attentiveness and or memory impairments. This compound is used to boost cognitive function, aiding in maintaining brain health for the elderly while also offering intellectual stimulation benefits for typical adults.
  • Inquiry Price
Size
QTY
AUT2
AUT-2, AUT 2
T2019871311137-58-2
AUT2 is a Kv3.1 channel modulator with the potential to treat sensory hyperreactivity in patients with FXS by shifting the activation of high-threshold currents to more negative potentials. This shift reduces high-threshold K+ currents and increases low-threshold K+ currents in neurons, restoring wave IV of the ABR. Due to its ability to regulate neuronal excitability, AUT2 is also promising for the treatment of hearing impairments.
  • Inquiry Price
Size
QTY
AChE/BChE-IN-25
T203222
AChE BChE-IN-25 (Compound 6e) is an orally active inhibitor of hAChE and eqBChE, with IC50 values of 7.9 nM and 0.79 nM, respectively. This compound exhibits antioxidant activity, effective in scavenging free radicals with an IC50 of 22.91 μM. AChE BChE-IN-25 demonstrates neuroprotective effects by reducing mitochondrial and cellular oxidative stress in a Drosophila Alzheimer's model and improves spatial and cognitive memory impairments induced by Scopolamine in mouse models.
  • Inquiry Price
Size
QTY
Ro4368554
T204915478082-99-4
Ro4368554 is a selective 5-HT6 antagonist capable of crossing the blood-brain barrier. It can reverse memory deficits caused by scopolamine and tryptophan depletion. Ro4368554 is applicable for research related to memory impairments.
  • Inquiry Price
10-14 weeks
Size
QTY
7BIO
T22012916440-85-2
7-bromoindirubin-3'-oxime (7BIO) is a caspase independent nonapoptotic cell death inducer. 7BIO is an inhibitor of FLT3, DYRK1A, DYRK2, Aurora B and Aurora C kinases.
  • Inquiry Price
Size
QTY
AF267
(±)AF 267,(±) AF 267,(±)-AF 267,AF 267,AF-267
T25005168818-83-5
AF267 is a M1 muscarinic agonist that works by restoring cognitive impairments.
  • Inquiry Price
6-8 weeks
Size
QTY
OAB-14
OAB 14,OAB14
T337662140911-49-3
OAB-14 is a Bexarotene derivative that improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice. OAB-14 effectively ameliorates the dysfunction of the endosomal-autophagic-lysosomal(EAL) pathway in APP/PS1 transgenic mice [1] [2].
  • Inquiry Price
6-8 weeks
Size
QTY
SAR502250
T35560503860-57-9
SAR502250 is a potent, selective, ATP-competitive, orally active, and brain-penetrant GSK3 inhibitor with a human GSK-3β IC50 value of 12 nM, exhibiting antidepressant-like activity and being researched for potential application in Alzheimer's disease (AD) treatment.
  • Inquiry Price
8-10 weeks
Size
QTY
Deacetylforskolin
T3672064657-20-1
Deacetylforskolin is a diterpene and a derivative of forskolin that has been found inC. forskohliiand has diverse biological activities.1,2,3,4It activates rat adipocyte adenylyl cyclase (IC50= 20 μM) and inhibits glucose transport in rat adipocyte plasma membranes.2Deactylforskolin (30-1,000 μg/kg) reduces blood pressure in spontaneously hypertensive rats.3It also attenuates hypercapnia-induced impairments in the passive avoidance response in mice.4 1.Gabetta, B., Zini, G., and Danieli, B.Minor Diterpenoids of Coleus forskohliiPhytochemistry28(3)859-862(1989) 2.Joost, H.G., Habberfield, A.D., Simpson, I.A., et al.Activation of adenylate cyclase and inhibition of glucose transport in rat adipocytes by forskolin analogues: structural determinants for distinct sites of actionMol. Pharmacol.33(4)449-453(1988) 3.Bhat, S.V., Dohadwalla, A.N., Bajwa, B.S., et al.The antihypertensive and positive inotropic diterpene forskolin: Effects of structural modifications on its activityJ. Med. Chem.26(4)486-492(1983) 4.McCulloch, A.J., Thomson, T.A., and Deacon, R.Hypoxic amnesia and its reversal with forskolinBiochem. Soc. Trans.17(1)212-213(1988)
  • Inquiry Price
Size
QTY
Amyloid-β (25-35) Peptide (human) (trifluoroacetate salt)
T37370
Amyloid-β (25-35) (Aβ (25-35)) is an 11-residue fragment of the Aβ protein that retains the physical and biological characteristics of the full length peptide. It forms fibrils that react to thioflavin T and Congo red and are organized in a cross-β arrangement of β-strands similar to Aβ (1-40) and Aβ (1-42) fibrils. Aggregated Aβ (25-35) decreases the viability of rat adrenal PC12 cells. It also decreases the viability of primary rat cortical neurons at concentrations ranging from 1 nM to 30 μM. In vivo, intracerebral injection of Aβ (25-35) (20 nmol) in rats induces lesions of neuronal and tissue loss. Aggregated Aβ (25-35) administered intracerebroventricularly to rats induces learning and memory impairments in the Y-maze, novel object recognition, and contextual fear conditioning tests.
  • Inquiry Price
Size
QTY
[(3R)-3-Hydroxydodecanoyl]-L-carnitine
T375161469900-99-9
[(3R)-3-Hydroxydodecanoyl]-L-carnitine is an endogenous metabolite[1].
  • Inquiry Price
Size
QTY
DSR-141562
T394212007975-22-4
DSR-141562 is a new compound that can be taken orally and has a specific ability to inhibit phosphodiesterase 1 (PDE1) in the brain. This compound exhibits a preference for inhibiting human PDE1B, with an IC50 value of 43.9 nM. It also shows moderate inhibition of human PDE1A (IC50 = 97.6 nM) and PDE1C (IC50 = 431.8 nM). DSR-141562 is particularly useful in the study of positive symptoms, negative symptoms, and cognitive impairments associated with schizophrenia.
    7-10 days
    Inquiry
    HFI-419
    T612581110650-72-0
    HFI-419 is a potent inhibitor of insulin-regulated aminopeptidase (IRAP) with a K i value of 0.48 μM. It is utilized in research pertaining to cognitive and memory impairments, including Alzheimer's disease, brain trauma, and stroke [1].
    • Inquiry Price
    6-8 weeks
    Size
    QTY
    BChE-IN-13
    T613422700896-73-5
    BChE-IN-13 (Compound 17c) is an orally active, potent, and selective inhibitor of Butyrylcholinesterase (BChE), exhibiting IC50 values of 0.22 μM and 0.016 μM for eqBChE and hBChE, respectively. BChE-IN-13 enhances memory and cognitive impairments, making it valuable for Alzheimer's disease (AD) research [1].
    • Inquiry Price
    6-8 weeks
    Size
    QTY
    BChE-IN-4
    T616692304818-41-3
    BChE-IN-4 is a highly potent inhibitor of the enzyme butyrylcholinesterase, capable of crossing the blood-brain barrier. It effectively reduces learning and memory impairments resulting from a deficiency in cholinergic activity in a mouse model. BChE-IN-4 holds promise for further investigation in the field of Alzheimer's disease research [1].
    • Inquiry Price
    6-8 weeks
    Size
    QTY